{"name":"Teva Pharma GmbH","slug":"teva-pharma-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Budesonide, Formoterol Fumarate Dihydrate","genericName":"Budesonide, Formoterol Fumarate Dihydrate","slug":"budesonide-formoterol-fumarate-dihydrate","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Budesonide, Formoterol Fumarate Dihydrate","genericName":"Budesonide, Formoterol Fumarate Dihydrate","slug":"budesonide-formoterol-fumarate-dihydrate","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxNOWREcVU3QjZfNnp0YTFJaHJjMVoxWWpKY2JpSE80RUlXZUt6LUpBOVlrREdoYWNndERIZkZkRU5QRFVCVi03NjEzRXg3bjZHei1BOENFMkEwZS1nTGpUVGtnY2trVzRqTVFsRThaa181dDlaakFBd1FZd0tvdm9UTzFEWG9Ganhzc0JCTXkwSU1sN04zU3BWZmFfWWU3YXFEanZDa2dCTmZzVTFPak5INkVtTjJlSWxVdzlYeUJrTVNMUi1uLXZ6a1NrNERSbVcyU0VWUGM5dmxIT3dOMlg2c2xSN2hudy1pSnR2b2pRVW1tWTl2Vm9ZOEI0cw?oc=5","date":"2025-11-25","type":"regulatory","source":"Quiver Quantitative","summary":"Teva Pharmaceutical Industries Ltd. Secures EU Approval for Biosimilars PONLIMSI and DEGEVMA, Enhancing Bone Health Treatment Access | TEVA Stock News - Quiver Quantitative","headline":"Teva Pharmaceutical Industries Ltd. Secures EU Approval for Biosimilars PONLIMSI and DEGEVMA, Enhancing Bone Health Trea","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNMUZ0R2ZSdmJseFVmOHNBdThZNUx1U3BUbXNBS2NBZzdBaU8xcjlYdEpyejdKZUhQVXU5OEM2dHNOMklmNVVhNGtib3ZRWW9Qd2FnQnRrNllVdVNweDRxUmV4RWw5WTh3dVNIZkhURS1seE1UQm83bDRqUjdIeHlPdGpGUXNMZ3pxUEd0bEtUS1RuWlE?oc=5","date":"2025-11-25","type":"regulatory","source":"finance.yahoo.com","summary":"Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva® - finance.yahoo.com","headline":"Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Bio","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPd1dGa01XbzhHMmM2U0ZRSkhLYWttc1Y4RUFhRkh2MWt4blpXTTNzbGVrR0E1a1FiTkFua3Z2YjJGTGY4eWw4V056VGhjcVZNZlh6d3NUalU1YXBjODBVMGt1UmlEY1VReklEYUxBWFc0Wk91MHFXanlhaDJqVTQtUW5fSFNLbEhjazdZLU9Objk4V1JGTzdQQl9wUHZmUXdxTWdLWFVadG1mM1huTkxlckhKWkptQVlVUXctX2oxQkh1YnpRRVE?oc=5","date":"2025-11-20","type":"pipeline","source":"Fierce Pharma","summary":"Biomanufacturer Antheia bolsters commercial drug ingredients prospects with TAPI alliance - Fierce Pharma","headline":"Biomanufacturer Antheia bolsters commercial drug ingredients prospects with TAPI alliance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxPODJTSGlmWVFYRHNJUHRKWlNtYUtqcjBReXUybXQzSGpWTWF2RWdNOHlwWnozcGZZeXZIbGhzX2k3RzhTU0doWV93OFptZWlHRzBobTlrcTg0c2RWQ1JQTWt6NWFtVWdQVnNCU3g1dXFSNENTRmtqTG8yZG9ieUVFOU94M1NwZmlTNHRzUmRDYy02ZnFGb3RjVmhObWFPOGlyTGFsZHhtekhWOElaMENhU0wtYnM1cjZGSXQzYXFscDNvSUFKYlhUcHB3V3lMQnJHQTJSb1F3Y0xweWVwQ3lvRGxfVUtJWW4ycGhkYXVxR2xvb3d1ZDlHRWVWc2xFaXPSAYcCQVVfeXFMUEhLOXprZFhKZlpIRlJqU3hOLWs0Qlh1R2ZZLTFUakNKdUdVRkM1eVpoc3ZoS0U0ZlFIdVc1dmxiSFFVVUQ5TlNzSTRoRUhleENQeUNXRHdtX2hwOU42NWptd21xVE5uYjRMT1NHb0xKNUR5LUlGOW9yQWVFLXVTTlZqcWt0Tmt6NlJFc2VGM19EQnJ6UVpTbklJOEc2b3dZZ2dqWWYtdld1OEF1VGMyMl9aRTROR1YxRnBGcnFzdjJRdWU0SWpZNFhJS3pnVFdsVEVHUnF5UHVaRHNBMGNXS3F3cTVaeGFiVy1yekFVcWZwdDJpWkliMDFudTRCbW1KOUctQTg4SE0?oc=5","date":"2025-10-24","type":"deal","source":"Insider Monkey","summary":"Teva Pharmaceutical (TEVA) Enters Into a License Agreement With Prestige Biopharma for the Commercialization of Tuznue in Europe - Insider Monkey","headline":"Teva Pharmaceutical (TEVA) Enters Into a License Agreement With Prestige Biopharma for the Commercialization of Tuznue i","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPWWlQX0dpWnBucExoSXl1THp6MDFjWHZTZmZHZ29PbUNHVE5wQ1d5bzZvU0paMUxxMm1kUnJUTXJHdk81ME9xNUZBQnB2cmtyYlFaWEdRSzAycWV4N3VmaFBrZXp0aldzWFQ0NHpMY2NFM1l5T1VjRkdqMUc5SGNsQnpnMA?oc=5","date":"2025-09-23","type":"patent","source":"finance.yahoo.com","summary":"Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play? - finance.yahoo.com","headline":"Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxORlk1OUg3Tm8tbjQ1YTdpbERZQ242SUl2TUFiXzJwNHhWdl9fZ0FVanZpWXJSSUN1TEQtdzVfUjlTQnNqYVRyeWc1MjQxSU9oVUw4cmxVaTBlTDRjZVdfTG9MMVpnZFB3OWY0OUxsVFU1a1YyaTBza0o0VHU5OTkyYTk3YkFvU3B1OUV4c0ZNMXNaNFBuQTFUU1NkQ0FUODZMQXdLZERrY3RzT0sySkdYdWMtMUJwYTFNTU15VE9PXzFFZ3VabEFleXgxN0xkQ294U09YQ2RDeWpxNzVCcE4wTmJpNEtxYWN6eWJJNFVNM29Qa2hyQkNab3UtNmxVZw?oc=5","date":"2025-09-09","type":"regulatory","source":"globenewswire.com","summary":"Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy - globenewswire.com","headline":"Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE01ejQ5ME1BbjRMVkxPT3ZFVVY4ZU93NjNFMEpBcmxmVlpmYkhPWUhkTlRkdjVFaHBlX2lZQ2Jsc2tnTHI4R0ZRc2FBa1BNQ2R4RmlDQ3lDWUNvWEE2MTdWU3NBYzhZYlUxRU12YUd30gFyQVVfeXFMTlRLT1Mza29sR2ozS3YxcDF6QjZvMW9KWTYxU0tadVRRRVdKajZMa1lPRHNpUkZhMm9rSXZEN1FKSWlmeEU0WTVvdEVIN1NSTjI0NC1NZnZyelpOa2RlYXpOQ0tleko1SnZnT1VkM1dkN253?oc=5","date":"2025-05-26","type":"deal","source":"koreabiomed.com","summary":"Prestige Biopharma inks European licensing deal with Teva for Herceptin biosimilar - koreabiomed.com","headline":"Prestige Biopharma inks European licensing deal with Teva for Herceptin biosimilar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNR2dhR2tsRWUza0RlUkxrLWtERUxHYmp5ZG9oejNaSng3OXppMEpLT1J2c1gxQkpYOXdlRmtzdVZ5dUFweDZGcmVqNF9uUnRfRUxwcnpCOU16Ulp3VldzUHR0eVJwZ2NZQTlpVktDbDFPdlFrNmU5TWc2ZkYyZmg2NzNXeEg5OE5lb1VsV3JnNGpFWEFCNElnTFVodU5XRTR0Vmd4dU1sU0VvT05LVFAwMQ?oc=5","date":"2025-05-08","type":"trial","source":"Fierce Pharma","summary":"Teva plots thousands of job cuts as restructuring drive enters 'acceleration' phase - Fierce Pharma","headline":"Teva plots thousands of job cuts as restructuring drive enters 'acceleration' phase","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQXy1jRUp1X1Y3eEJBVXVOaXo5amJQVzhwQnBoMkxieVNvUzQ0T2VwbmFOSmRlLUh2OVFTYTVLRFpzMV9xZE1mQUFsQlgwSEtvQV9xcmFsNWJmOUZ1QjBDUDVUX004MVluT285dlVzMW1sRHNYUG1qelB0b0g1SnIzcUsxZEVZLXRDR0FJdzExaUswVTFRTGNFY2l3ZVBEZm8xaWZQa0tQaEw4cXdLak5iVHppVHh0dDVnNjYtdWx5MUd3b3ZzSnpxWFRYa3pRcmRaX3BLRHlWWkhmV2Y4M0E?oc=5","date":"2025-01-13","type":"deal","source":"Ophthalmology Times Europe","summary":"Teva partners with Klinge Biopharma, Lotus Pharmaceutical for commercialisation of Formycon’s FYB203 (biosimilar aflibercept) - Ophthalmology Times Europe","headline":"Teva partners with Klinge Biopharma, Lotus Pharmaceutical for commercialisation of Formycon’s FYB203 (biosimilar afliber","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQR1RqUGRkNnpPVm9ISm9tejN1QzJGcV9yeTRJb21lX0VyX3FwczZZTW1qWU9mMU1hSW0tUk5wWTFHa1U0czVneWlqSGVFUGFTOUhTR2hTQlpkcmM1clVfTmdJMC1ERWxqQTJ5REJaSmNPZEptdnk1OVQ1dzhzMmtTbGZiaHVjM2VyeWRpUFliQTdWUUJjVXJETUUyQV9uX3Y5b1NFX281eXRPV2ZNSkFCbFMxQTlTeFNxckFwcXRCVWozV0k4?oc=5","date":"2024-10-03","type":"deal","source":"Contract Pharma","summary":"Teva, mAbxience Expand Collaboration to Include an Additional Oncology Biosimilar - Contract Pharma","headline":"Teva, mAbxience Expand Collaboration to Include an Additional Oncology Biosimilar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOdDllVWh4MnROWlpKNWpjbEVJcFJyMjRIVG9UR1lENkJKZ1VxTkFBUDlfODh6VEw2VDNPSmpTQnVCQ1ZsUU1JcGJXd25DcDFQTFp6Q3hUZ28wYjNTaExZX0ZTWUw1T250QlpWOXM5em9SeDJfTXNlbWIycUlEUERaOFphOFJHYWlRdmZOU3dxUXFyWENMOGZ3SEowYW5fVm1kZm1Ob1BQZU9sbVJtMktWcQ?oc=5","date":"2023-03-14","type":"patent","source":"Akin","summary":"Federal Circuit Affirms Invalidation of Purdue Pharma’s OxyContin Patents - Akin","headline":"Federal Circuit Affirms Invalidation of Purdue Pharma’s OxyContin Patents","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxNbkhXOVhSTGRQU2ljSzlBdkw1VWZ0dmNkczdkVE1EZlhrekVpRDI5TjZMUWl2YmkyWFhHMFRsU1Q0clNTcWtNVWZwa2J6NUdJZUpoaFhuenZySHdyLTl5cnhDb1dHQ0lfclJqTzZ0eVVnMnFvWGxQb3hFN0pocnJZT2EzdW44cjlVQkFnUkxqVGhPaUMyQzNXcENaWnpWVzg5SWNhcWdQSFBqaUw4WUNEVlJIQXc3OWtRS0VRMUdNWVdaTXNSYzI1WjQyb1JfZ0FKOGc?oc=5","date":"2021-10-27","type":"earnings","source":"reuters.com","summary":"Teva Pharm Q3 profit misses estimates, sees recovery into Q4 - reuters.com","headline":"Teva Pharm Q3 profit misses estimates, sees recovery into Q4","sentiment":"negative"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}